These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24086580)

  • 1. Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody.
    Wang L; He Y; Zhang G; Ma J; Liu C; He W; Wang W; Han H; Boruah BM; Gao B
    PLoS One; 2013; 8(9):e75589. PubMed ID: 24086580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of the bispecific antibody IgG subclass on T cell redirection.
    Kapelski S; Cleiren E; Attar RM; Philippar U; Häsler J; Chiu ML
    MAbs; 2019; 11(6):1012-1024. PubMed ID: 31242061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 as a promising target for cytotoxicity T cells in human melanoma therapy.
    Ma J; Han H; Liu D; Li W; Feng H; Xue X; Wu X; Niu G; Zhang G; Zhao Y; Liu C; Tao H; Gao B
    PLoS One; 2013; 8(8):e73261. PubMed ID: 24015299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens.
    Moore GL; Bautista C; Pong E; Nguyen DH; Jacinto J; Eivazi A; Muchhal US; Karki S; Chu SY; Lazar GA
    MAbs; 2011; 3(6):546-57. PubMed ID: 22123055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific HER2 x CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overexpressing xenografts in nude mice.
    Shalaby MR; Carter P; Maneval D; Giltinan D; Kotts C
    Clin Immunol Immunopathol; 1995 Feb; 74(2):185-92. PubMed ID: 7828373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
    Biburger M; Weth R; Wels WS
    J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a Novel Bispecific Antibody That Activates T Cells
    Chornoguz O; Leettola CN; Leander K; Brosnan K; Emmell E; Chiu ML; Santulli-Marotto S
    Monoclon Antib Immunodiagn Immunother; 2019 Dec; 38(6):242-254. PubMed ID: 31825302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific Her2 × cotinine antibody in combination with cotinine-(histidine)2-iodine for the pre-targeting of Her2-positive breast cancer xenografts.
    Yoon S; Kim YH; Kang SH; Kim SK; Lee HK; Kim H; Chung J; Kim IH
    J Cancer Res Clin Oncol; 2014 Feb; 140(2):227-33. PubMed ID: 24292501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
    Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
    J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (carcinoma embryonic antigen) positive tumor cells in vitro efficiently.
    Wang XB; Zhao BF; Zhao Q; Piao JH; Liu J; Lin Q; Huang HL
    J Biochem; 2004 Apr; 135(4):555-65. PubMed ID: 15115782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin.
    Müller D; Karle A; Meissburger B; Höfig I; Stork R; Kontermann RE
    J Biol Chem; 2007 Apr; 282(17):12650-60. PubMed ID: 17347147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28.
    Grosse-Hovest L; Brandl M; Dohlsten M; Kalland T; Wilmanns W; Jung G
    Int J Cancer; 1999 Jan; 80(1):138-44. PubMed ID: 9935244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Human VH Single Domains as Fc Fusions in Mammalian Cells.
    Abdelatti M; Schofield P; Christ D
    Methods Mol Biol; 2019; 1953():121-136. PubMed ID: 30912019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer.
    Kufer P; Mack M; Gruber R; Lutterbüse R; Zettl F; Riethmüller G
    Cancer Immunol Immunother; 1997; 45(3-4):193-7. PubMed ID: 9435872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan.
    Zhang X; Yang Y; Zhang L; Lu Y; Zhang Q; Fan D; Zhang Y; Zhang Y; Ye Z; Xiong D
    J Hematol Oncol; 2017 Feb; 10(1):56. PubMed ID: 28228105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of an anti-p185(HER2) (scFv-C(H)2-C(H)3)2 fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEEK.
    Vaidyanathan G; Jestin E; Olafsen T; Wu AM; Zalutsky MR
    Nucl Med Biol; 2009 Aug; 36(6):671-80. PubMed ID: 19647173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.
    McCall AM; Adams GP; Amoroso AR; Nielsen UB; Zhang L; Horak E; Simmons H; Schier R; Marks JD; Weiner LM
    Mol Immunol; 1999 May; 36(7):433-45. PubMed ID: 10449096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing Fc Domains in T cell-Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency.
    Wang L; Hoseini SS; Xu H; Ponomarev V; Cheung NK
    Cancer Immunol Res; 2019 Dec; 7(12):2013-2024. PubMed ID: 31615814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.